Physicians' Academy for Cardiovascular Education

PCSK9

UP TO DATE: Follow news, literature and expert perspectives on PCSK9 inhibition in lipid management

Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine

3' education - Nov. 16, 2023 - Andrew Bellinger, MD, PhD

Three fascinating new strategies for lipid management

3' education - Nov. 13, 2023 - Karol Watson, MD, PhD

PCSK9i: Benefits across the spectrum of cardiovascular disease

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD

New insights on CETP inhibition from genetic research and clinical trials

10' education - Oct. 5, 2023 - John Kastelein, MD, PhD

Oral cholesterol-lowering therapies: The basis of prevention

10' education - Oct. 2, 2023 - Lale Tokgözoğlu, MD

The evolving need and challenges to reach LDL-c targets in high-risk patients

10' education - Sep. 14, 2023 - Kausik Ray, MD

Large study assessing long-term efficacy and safety of PCSK9 siRNA

3' education - Sep. 4, 2023 - R. Scott Wright, MD

4-year follow-up data on efficacy and safety of PCSK9 siRNA

5' education - May 8, 2023 - Kausik Ray, MD

Imaging study with PCSK9 inhibitor in patients with stable CAD

5' education - Apr. 17, 2023 - Annapoorna Kini, MD

Interesting developments in the field of PCSK9 inhibition

3' education - Mar. 21, 2023 - Prof. Deepak Bhatt, MD

Promising results for oral PCSK9i to proceed to phase 3 trials

3' education - Mar. 8, 2023 - Prof. Christie Ballantyne, MD

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD

Real-world evidence with PCSK9i mAb; implications and lessons for current clinical use

10' education - Oct. 12, 2022 - Raul Santos, MD, PhD & Prof. Maciej Banach, MD, PhD

The clinical challenge: a patient with multiple risk factors

10' education - Oct. 7, 2022 - Prof. Erik Stroes, MD, PhD

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD

Changing paradigms in LDL-c reduction

10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD

Optimizing treatment for patients with HoFH

10' education - July 13, 2022 - Prof. Erik Stroes, MD, PhD

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Phase 3 trial does not confirm efficacy of PCSK9 siRNA in HoFH

Literature - Nov. 20, 2023 - Raal F, et al. - Circulation. 2023

The ORION-5 trial, in which 56 patients with homozygous familial hypercholesterolemia (HoFH) were treated with inclisiran or placebo, did not meet its primary endpoint of LDL-c reduction at 150 days. The PCSK9 level did decrease in the inclisiran group.

Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine

3' education - Nov. 16, 2023 - Andrew Bellinger, MD, PhD
**AHA 2023** Andrew Bellinger talks about VERVE-101, a novel base editing medicine which makes a single base pair change in the //PCSK9// gene to lower PCSK9 and LDL-c. He shares three important observations of the first-in-human study with VERVE-101 in patients with HeFH and ASCVD.

AHA 2023 Andrew Bellinger talks about VERVE-101, a novel base editing medicine which makes a single base pair change in the PCSK9 gene to lower PCSK9 and LDL-c. He shares three important observations of the first-in-human study with VERVE-101 in patients with HeFH and ASCVD.

Three fascinating new strategies for lipid management

3' education - Nov. 13, 2023 - Karol Watson, MD, PhD

AHA 2023 "This is such a fascinating time in lipid therapeutics," says Karol Watson. She substantiates this by summarizing three late-breaking science studies with VERVE-101, lepodisiran and recaticimab.

First-in-human trial results of PCSK9 gene editing therapy in HeFH and ASCVD

News - Nov. 13, 2023

AHA 2023 One dose of VERVE-101, a CRISPR base editing therapy that inactivates PCSK9, resulted in dose-dependent reductions of PCSK9 protein and LDL-c in 10 HeFH patients with ASCVD and uncontrolled hypercholesterolemia and was overall safe.

Long-term efficacy and safety data of PCSK9 antibody in post-ACS patients

Literature - Oct. 30, 2023 - Goodman SG, et al - J Am Heart Assoc. 2023

In a post-hoc analysis of the ODYSSEY OUTCOMES trial, alirocumab reduced MACE in post-ACS patients who were eligible for 3 to 5 years of follow-up compared with placebo.

PCSK9i: Benefits across the spectrum of cardiovascular disease

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD
Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.

Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.

New insights on CETP inhibition from genetic research and clinical trials

10' education - Oct. 5, 2023 - John Kastelein, MD, PhD
“We are only now beginning to understand how CETP inhibition works in terms of protection against cardiovascular disease”, says John Kastelein. He explains what we have learned from genetic research and clinical trials with CETP inhibitors.

“We are only now beginning to understand how CETP inhibition works in terms of protection against cardiovascular disease”, says John Kastelein. He explains what we have learned from genetic research and clinical trials with CETP inhibitors.

Oral cholesterol-lowering therapies: The basis of prevention

10' education - Oct. 2, 2023 - Lale Tokgözoğlu, MD

"Oral cholesterol-lowering therapies are the basis of cardiovascular disease prevention", says Lale Tokgözoğlu. In this video, she talks about oral therapies.

Angiographic stenosis regression with PCSK9 inhibitor in acute MI

Literature - Sep. 14, 2023 - Bär S, et al. - EuroIntervention. 2023

A prespecified substudy of the PACMAN-AMI trial showed 1 year of alirocumab, on top of rosuvastatin, resulted in regression of the angiographic diameter stenosis of non-obstructive coronary lesions in acute MI patients, compared with an increase with placebo.

The evolving need and challenges to reach LDL-c targets in high-risk patients

10' education - Sep. 14, 2023 - Kausik Ray, MD
According to the latest registries, the majority of high- and very high-risk patients do not achieve the 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.

According to the latest registries, the majority of high- and very high-risk patients do not achieve the 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.

Small PCSK9 binding protein reduces LDL-c and is safe in patients with HeFH

News - Sep. 5, 2023

ESC Congress 2023 Investigators of the phase 3 LIBerate-HeFH trial reported data on the efficacy and safety of the small PCSK9 binding protein lerodalcibep in patients with heterozygous FH (HeFH).

Long-term efficacy and safety data of PCSK9 siRNA in patients with high CV risk and elevated LDL-c

News - Sep. 4, 2023

ESC Congress 2023 The ORION-8 trial, an open-label extension of ORION-3/9/10/11, demonstrated the efficacy, safety and tolerability of inclisiran in patients with high cardiovascular risk and elevated LDL-c.

PCSK9